Diagnosing Lower-Risk MDS

Now Viewing

EP: 1.Diagnosing Lower-Risk MDS

EP: 2.Classifying MDS: Updated WHO and ICC Guidelines

EP: 3.Risk Stratification Tools for MDS: IPSS, IPSS-R, IPSS-M

EP: 4.Importance of Early Detection and Unmet Needs in MDS

EP: 5.Lower-Risk MDS: Treatment Goals and Options

EP: 6.Choosing Treatment for Lower-Risk MDS

EP: 7.Role of Stem Cell Transplant in MDS

EP: 8.MEDALIST: Clinical Implications in Lower-Risk MDS

EP: 9.Imetelstat and Canakinumab in Lower-Risk MDS

This is a video synopsis/summary of a Precision Medicine series featuring Hana Safah, MD, and Jamie Koprivnikar, MD. Safah and Koprivnikar discuss diagnosis and risk stratification of lower-risk myelodysplastic syndromes (MDS). Initial work-up rules out other causes of cytopenia before bone marrow biopsy to assess blasts and dysplasia. Cytogenetics, fluorescence in situ hybridization, and molecular mutation panels also are utilized, with increasing emphasis on mutations to enable precise classification.

Recently, the Mutation-Enhanced International Prognostic Scoring System (MIPSS) has helped patient stratification into risk groups beyond prior systems like the revised IPSS. By integrating genetic data, MIPSS allows more personalized prognosis and management decisions in MDS.

Ongoing advances in molecular characterization continue to shape diagnosis, prognostication, and treatment selection for this heterogeneous disease. The discussants note excitement regarding recent data at the 65th American Society of Hematology Annual Meeting and Exposition highlighting the promise of molecularly targeted approaches.

Video synopsis is AI generated and reviewed by Targeted Oncology™ editorial staff.